Treatment of pulmonary arterial hypertension in congenital heart disease in Singapore versus the Netherlands: age exceeds ethnicity in influencing clinical outcome

Annelieke C.m.j. van Riel, Mark J. Schuuring, Irene D. van Hessen, Arie P.j. van Dijk, Elke S. Hoendermis, James Yip, Barbara J.m. Mulder, Berto J. BoumaNetherlands 2016 · DOI

Abstract

Patients from Singapore had a worse clinical performance at baseline compared with the PAH-CHD patients from the Netherlands. No relation between ethnicity and improvement in 6MWT after PAH-specific therapy was found. Age at initiation of PAH-specific therapy was the strongest predictor of treatment efficacy and mortality, emphasising the need for early initiation of treatment in these patients.

Introduction

Pulmonary arterial hypertension (PAH) is a life-threatening complication for many individuals born with congenital heart disease (CHD). While international guidelines for PAH-CHD treatment exist, they are predominantly based on clinical trials conducted in Western nations, where Asian populations represent only 6–7% of participants. This creates a significant knowledge gap: do biological differences or socioeconomic factors mean that Asian patients require different treatment strategies? This study sought to determine if ethnicity and geography influence how patients present and how they respond to advanced PAH therapies by comparing cohorts from Singapore and the Netherlands.

Methods

The researchers conducted a retrospective analysis of two nationwide registries from 2004 to 2013. The study compared 45 Dutch patients from a prospective multicenter cohort and 29 Singaporean patients from a dedicated PAH-CHD registry at the National University Hospital.

Patient selection flowchart for the Dutch and Singaporean cohorts.

Treatment protocols differed between the two groups: Dutch patients were predominantly started on endothelin receptor antagonists (ERAs), while Singaporean patients were primarily treated with phosphodiesterase-type-5 (PDE-5) inhibitors. The primary metric for exercise capacity was the Six-Minute Walk Test (6MWT). To account for physical differences between populations, results were calculated as a percentage of the "predicted value" based on age, sex, height, and weight. Linear mixed model analysis tracked changes over time, and Cox proportional hazard analyses identified determinants of mortality.

Results

Baseline Differences and Treatment Response

Singaporean patients presented with significantly worse clinical performance at baseline, including lower 6MWT distances (312m vs. 395m), higher systolic pulmonary arterial pressure (99 mmHg vs. 76 mmHg), and lower peak oxygen consumption ($VO_2$) (35% vs 49% of predicted, p=0.01). This "late start" in Singapore may be attributed to socioeconomic barriers; in Singapore, PAH medications are often not fully reimbursed, creating an economic burden that may delay treatment.

Despite these baseline differences and the use of different drug classes (ERAs vs. PDE-5 inhibitors), the improvement in exercise capacity was significant across both cohorts. Both groups showed a marked increase in 6MWT distance during the first year of treatment, with the Singaporean cohort showing a higher relative increase compared to the Dutch cohort (p=0.024), likely due to their lower starting baseline.

6MWT distance (a) and % predicted (b) over 12 months of therapy.

Predictors of Success and Survival

The most striking finding was that age at the start of therapy was the strongest predictor of both treatment efficacy and mortality. For every 5-year decrease in age at treatment initiation, there was a +4.5% improvement in 6MWT (p=0.017). Age at initiation remained the only significant determinant of 6MWT improvement when corrected for ethnicity, sex, and baseline performance. Interestingly, survival was significantly lower in the Dutch population (p=0.02), though the authors note this cohort was slightly older and had different shunt characteristics.

Discussion and Conclusion

While the study is limited by its retrospective nature and small sample size, the findings suggest that current international guidelines for PAH-CHD are broadly applicable across different ethnicities. The universal efficacy of therapy indicates that geography and ethnicity are less critical than the timing of intervention.

The study emphasizes the urgent need for healthcare policy changes in regions like Singapore to ensure that high-cost PAH therapies are accessible earlier in the disease progression. Given that age at initiation is the primary driver of positive outcomes, early intervention is essential to improving survival and quality of life for PAH-CHD patients globally.

Summary updated

Abstract

Patients from Singapore had a worse clinical performance at baseline compared with the PAH-CHD patients from the Netherlands. No relation between ethnicity and improvement in 6MWT after PAH-specific therapy was found. Age at initiation of PAH-specific therapy was the strongest predictor of treatment efficacy and mortality, emphasising the need for early initiation of treatment in these patients.
BibTeX
@inproceedings{riel2016treatment,
  author = {Annelieke C.M.J. van Riel and Mark J. Schuuring and Irene D. van Hessen and Arie P.J. van Dijk and Elke S. Hoendermis and James Yip and Barbara J.M. Mulder and Berto J. Bouma},
  title = {{Treatment of pulmonary arterial hypertension in congenital heart disease in Singapore versus the Netherlands: age exceeds ethnicity in influencing clinical outcome}},
  booktitle = {Netherlands},
  year = {2016},
  doi = {10.1007/s12471-016-0820-z},
}
Figure